Childhood- and adult-onset lupus: An update of similarities and differences

Expert Review of Clinical Immunology

Volumn 5, Issue 4, 2009, Pages 391-403

  Papadimitraki, Eva D ^a   Isenberg, David A ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adult onset; ANA; Antiphospholipid syndrome; BILAG; Childhood onset; CNS lupus; Cyclophosphamide; Growth delay; Nephritis; Rituximab; SDI; Steroids; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID;

ADULT; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILD DEVELOPMENT; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GROWTH RETARDATION; HIRSUTISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; OBESITY; ONSET AGE; OSTEOPOROSIS; PHOTOSENSITIVITY; PREVALENCE; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; RHEUMATIC DISEASE; SCORING SYSTEM; SEX DIFFERENCE; SKIN MANIFESTATION; SOCIAL ASPECT; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

EID: 77649084545     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.29     Document Type: Review

References (102)

1. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmigham, England: relationship to ethnicity and country of birth. Arthritis Rheum. 38, 551-558 (1995)
2. Abu-Shakra M, Urowitz NB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus: results from a single center. II. Predictor variables for mortality. J. Rheumatol. 22, 1265-1270 (1995)
3. Font J, Cervera R, Espinosa G et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological in 35 patients and comparison with SLE characteristics in adults. Ann. Rheum. Dis. 57, 456-459 (1998)
4. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset systemic lupus erythematosus. A comparison of onset, clinical features, serology and outcome. Br. J. Rheumatol. 34, 866-872 (1995)
5. Janwityanujit S, Totemchokchyakarn K, Verasertniyom O, Vanichapuntu M, Vatanasuk M. Age related differences on clinical and immunological manifestations of SLE. Asian Pac. J. Allergy Immunol. 13(2), 145-149 (1995)
6. Carreno L, Lopez-Longo FJ, Monteagudo I et al. Immunological and clinical differences between juvenile and adult onset systemic lupus erythematosus. Lupus 8, 287-292 (1999)
7. Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silvermann ED. Difference in disease fearures between childhoodonset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 58(2), 556-562 (2008)
8. Hersh AO, von Scheven E, Yazdany J et al. Differences in long term disease activity and treatment of adult patients wth chidhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum. 61(1), 13-20 (2009)
9. Tucker LB, Uribe AG, Fernandez M et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 17(4), 314-322 (2008)
10. Pande J, Sekharan NG, Kailash S et al. Analysis of clinical and laboratory profile in Indian childhood systemic lupus erythematosus and its comparison with SLE in adults. Lupus 2(2), 83-87 (1993)
11. Tucker LB, Menon S, Schaller JG et al. Comparison of adult and childhood onset systemic lupus erythematosus. Br. J. Rheumatol. 33, s84 (1994)
12. Jimenez S, Cervera R. Font J, Ingelmo M. The epidemiology of systemic lupus erythematosus. Clin. Rev. Allergy Immunol. 25, 3-12 (2003)
13. Bogdanovitc R, Nikolic V, Pasic S et al. Lupus nephritis in childhood. A review of 53 patients followed at a single center. Pediatr. Nephrol. 19, 36-44 (2004)
14. Benseler SM, Silverman ED. Systemic lupus erythematosus. Pediatr. Clin. North Am. 52, 443-467 (2005)
15. Mok CC. Prognostic factors in lupus nephritis. Lupus 14, 39-44 (2005)
16. Miettunen PM, Ortiz-Alvarez O, Petty RE et al. Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus. J. Rheumatol. 31, 1650-1654 (2004)
17. Brunner H, Silverman E, Bombardier C, Feldman B. Risk factors for damage in childhood onset systemic lupus erythematosus. Arthritis Rheum. 46, 436-444 (2002)
18. Swaak AJ, Nossent JC, Bronsveld W et al. Systemic lupus erythematosus II. Observations on the occurrence of exacerbations in the disease course. Dutch experience with 110 patients studied prospectively. Ann. Rheum. Dis. 48, 455-460 (1989) (Pubitemid 19158931)
19. Lehman TJ, McCurdy DK, Bernstein BH, King KK, Hanson V. Systemic lupus erythematosus in the first decade of life. Pediatrics 83, 235-239 (1989)
20. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 35, 630-640 (1992)
21. Klein-Gitelman M, Reiff A, Silverman ED. Systemic lupus erythematosus in childhood. Rheum. Dis. Clin. North Am. 28, 561-577 (2002)
22. Barron KS, Silverman ED, Gonzales J, Reveille JD. Clinical, serologic and immunogenetic studies in childhood onset systemic lupus erythematosus. Arthritis Rheum. 36, 348-354 (1993)
23. White PH. Pediatric systemic lupus erythematosus and neonatal lupus. Rheum. Dis. Clin. North Am. 20(1), 119-127 (1994)
24. Baqi N, Moazami S , Singh A, Ahmad H, Balachandra S, Tejani A. Lupus nephritis in children. A longitudinal study of prognostic factors and therapy. J. Am. Soc. Nephrol. 7, 924-929 (1996)
25. Salah S, Lotfy HM, Sabry SM, Hamshary AE, Taher H. Systemic lupus erythematosus in Egyptian children. Rheumatol. Int. (2009) (Epub ahead of print)
26. Bakkaloglu A. Lupus nephropathy in children. Nephrol. Dial. Transplant. 16(Suppl. 6), 126-128 (2001)
27. Mok CC, Ying KY, Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus nephritis. Arthritis Rheum. 50, 2559-2568 (2004)
28. Lee BS, Cho HY, Kim EJ et al. Clinical outcomes of childhood lupus nephritis: a single center's experience Pediatr. Nephrol. 22, 222-231 (2007)
29. Zappitelli M, Duffy C, Bernard C et al. Clinicopathological study of the WHO classification in childhood lupus nephritis. Pediatr. Nephrol. 19, 503-510 (2004)
30. Austin HA 3rd, Boumpas DT, Vaughan EM, Baow JE. High risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol. Dial. Transplant. 10, 1620-1628 (1995)
31. Hari P, Bagga A, Mahajan P, Dinda A. Outcome of lupus nephritis in Indian children. Lupus 184, 348-354 (2009)
32. George PM, Tunnessen WW. Childhood discoid lupus erythematosus. Arch. Dermatol. 129, 613-617 (1993)
33. Prustowski SD, Gilliam JN. Discoid lupus erythematosus as a part of a larger disease spectrum. Correlation of clinical features with laboratory findings in lupus erythematosus. Arch. Dermatol. 111, 1448-1452 (1975)
34. Vitali C, Rencivelli W, Isenberg DA et al.; European Consensus Study Group for Disease Activity in SLE. A report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin. Exp. Rheumatol. 10, 527-539 (1992)
35. Trapani S, Camiciottoli G, Ermini M, Castellani W, Falcini F. Pulmonary involvement in childhood onset systemic lupus erythematosus. A report of five cases. Rheumatology (Oxford) 43, 587-591 (2004)
36. Swigris JJ, Fischer A, Gilles J, Meehan RT, Brown KK. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest 133, 271-280 (2008)
37. Lilleby V, Aalokken TM, Johansen B, Forre O. Pulmonary involvement in patients with childhood onset systemic lupus erythematosus. Clin. Exp. Rheumatol. 24(2), 203-208 (2006)
38. Yeh TT, Yang YH, Lin YT, Lu CS, Chiang BL. Cardiopulmonary involvement in pediatric systemic lupus erythematosus: a twenty year retrospective analysis. J. Microbiol. Immunol. Infect. 40, 525-531 (2007)
39. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman AD. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus. A longitudinal study. J. Pediatr. 152(4), 550-560 (2008)
40. Kahl LE. The spectrum of pericardial tamponade in systemic lupus erythematosus. Report of ten patients. Arthritis Rheum. 35, 1343-1349 (1992)
41. Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 43(7), 924-929 (2004)
42. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44(10), 2331-2337 (2001)
43. Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J. Rheumatol. 26(11), 2363-2368 (1999)
44. Gazarian M, Feldman BM, Benson LN, Gilday DL, Laxer RM, Silverman ED. Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus. J. Pediatr. 132, 109-116 (1998)
45. Sarkissian T, Beyene J, Feldman B, McCrindle B, Silvermann ED. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum. 56, 631-638 (2007) (Pubitemid 46271989)
46. Stichweh D, Pascual V. Lupus eritematoso sistemico pediatrico. An. Pediatr. (Barc.) 63(4), 321-329 (2005)
47. Posadas-Romero C, Torres-Tamayo M, Zamora-Gonzalez J et al. High insulin levels and increased low density lipoprotein oxidizability in pediatric lupus patients with systemic lupus erythematosus. Arthritis Rheum. 50, 160-165 (2004)
48. Costallat LT, Coimbra AN. Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset. Clin. Exp. Rheumatol. 12, 603-607 (1994)
49. Costallat LT, Coimbra AN. Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset. Clin. Exp. Rheumatol. 12, 603-607 (1994)
50. Stichweh D, Arce E, Pascual V. Update on pediatric systemic lupus erythematosus. Curr. Opin. Rheumatol. 16, 577-587 (2004)
51. Yu HH, Lee JH, Wang LC, Yang YH, Chiang BL. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus. A 20 year study. Lupus 15(10), 651-657 (2006)
52. Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J. Rheumatol. 23, 1981-1987 (1996)
53. Benseler SM, Silverman ED. Review: neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 16, 564 (2007)
54. Muscal E, Myones BL. The role of autoantibodies in pediatric neuropsychiatric systemic lupus erythematosus. Autoimmun. Rev. 6(4), 215-217 (2007)
55. Brey LB. Neuropsychiatric lupus. Clinical and imaging aspects. Bull. NYU Hosp. Joint Dis. 65(3), 194-199 (2007)
56. Appenzeller S, Rondina JM, Li LM et al. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum. 52, 2783-2789 (2005)
57. Driver CB, Wallace J, Lee JC et al. Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 59(3), 332-337 (2008)
58. Schmugge M, Revel-Vilik S, Hiraki L, Rand ML, Blanchette VS, Silverman ED. Thrombocytopenia and thrombembolism in pediatric systemic lupus erythematosus. J. Pediatr. 143, 666-669 (2003)
59. Gomez Puerta JA, Martin H, Amigo MC et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 84, 225-230 (2005)
60. Avcin T, Cimaz R, Silverman ED et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics 122, 1100-1107 (2008)
61. Berkun Y, Padeh S, Barash J et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum. 55, 850-855 (2006)
62. Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguire C. High impact of antiphospholipid syndrome on irreversible organ damage and survival in patients with systemic lupus erythematosus. Arch. Int. Med. 164, 77-82 (2004)
63. Irving KS, Sen D, Tahir H, Pilkington C, Isenberg DA. A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus. A retrospective review of cases. Rheumatology 46, 1171-1173 (2007)
64. Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the systemic lupus erythematosus disease activity index, British islet lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood systemic lupus erythematosus. Arthritis Rheum. 42, 1354-1360 (1999)
65. Ruperto N, Ravelli A, Cuttica R et al. for the Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Colaborative Study Group (PRCSG). The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum. 52, 2854-2864 (2005)
66. Gladman D, Urowitz M, Goldsmith C et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthitis Rheum. 40, 809-813 (1997)
67. Rahman P, Gladman DD, Urowitz MB. Early damage measured by the SLICC/ ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 10, 93-96 (2001)
68. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus - a 5-yr prospective study. Rheumatology 43, 1039-1044 (2004)
69. Stoll T, Seifert B, Isenberg D. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcomes in patients with systemic lupus erythematosus. Br. J. Rheumatol. 35, 248-254 (1996)
70. Dayal NA, Gordon C, Tucker L, Isenberg DA. The SLICC Damage Index; past, present and future. Lupus 11, 261-265 (2002)
71. Ruperto N, Ravelli S, Murray K et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermantomyositis. Rheumatology 42, 1452-1459 (2003)
72. Gutierez-Suarez R, Ruperto N, Gastaldi R et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinic/American College of Rheumatology Damage Index based on the analysis of 1015 patients with juvenileonset systemic lupus erythematosus. Arthritis Rheum. 54, 2989-2996 (2006)
73. Reichlin M, Broyles TF, Hubscher O et al. Prevalence of autoantibodies to ribosomal P proteins in juvenile onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum. 42, 69-75 (1999)
74. Jurencak R, Fritzler M, Tyrrell P, Hiraki L, Benseler S, Silverman E. Autoantibodies in pediatric systemic lupus erythematosus: ethnic grouping, cluster analysis and clinical correlations. J. Rheumatol. 36(2), 416-421 (2009)
75. Avin P, Rey C, Frappier JY. Therapeutic compliance in adolescents with chronic disease. Arch. Pediatr. 2(9), 874-882 (1995)
76. Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10 year follow-up data of the Euro-lupus Nephritis Trial comparing low dose versus high dose intravenous cyclophosphamide. Ann. Rheum. Dis. (2009) (Epub ahead of print)
77. Bertsias G, Boumpas DT. Update on the management of lupus nephritis: let the treatment fit the patient. Nat. Clin. Pract. Rheumatol. 4, 464-472 (2008)
78. Jones RB, Walsh M, Smith KG. What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis? Curr. Opin. Rheumatol. 21(3), 256-261 (2009)
79. Barillas-Arias L, Adams A, Angeles S, MacDerott EJ, Barinstein L, Lehman TJA. Combination of rituximab and cyclophosphamide for the treatment of childhood onset systemic lupus erythematosus. Arthritis Rheum. 54(Suppl.), S689-S690 (2006) (Abstract)
80. Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G. Rituximab therapy for juvenile onset systemic lupus erythematosus. Pediatr. Nephrol. 23, 13-19 (2008)
81. Lu TY, Ng KP, Cambridge G et al. A retrospective seven year analysis of the use of B cell depletion therapy in systemic lupus erythematous at University College London Hospital: the first fifty patients. Arthritis Care Res. 61, 482 (2009)
82. Melander S, Sallee M, Trolliet P et al. Rituximab in severe lupus nephritis; early B-cell depletion affects long-term renal outcome. Clin J. Am. Soc. Nephrol. 4(3), 579-587 (2009)
83. Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP. Rituximab an mycophenolate mofetil in relapsing lupus nephritis: a long term prospective study. Nephrol. Dial. Transplant. (2009) (Epub ahead of print)
84. Medeiros PB, Febronio MV, Bonfa E, Borba EF, Takiuti AD, Silva CA. Menstrual andhormonal alterations in juvenile systemic lupus erythematosus. Lupus 18(1), 38-43 (2009)
85. Demicrin G, Oner A, Erdogan O et al. Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative nephritis. Ren. Fail. 30(6), 603-609 (2008)
86. Lau KK, Ault BH, Jones DP, Butani L. Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil. J. Pediatr. Health Care 5, 282-288 (2008)
87. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J. Rheumatol. 9, 2103-2108 (2001)
88. Fujinaga S, Ohtomo Y, Hara S et al. Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low dose intravenous cyclophosphamide regimen. Pediatr. Nephrol. 23, 1877-1882 (2008)
89. Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus; current therapeutic approach. Curr. Pharm. Des. 14(13), 1261-1269 (2008)
90. Yancey CL, Doughty RA, Athreya BH. Central nervous system involvement in childhood systemic lupus erythematosus. Arthritis Rheum. 24, 1389-1395 (1981)
91. Baca V, Lavalle C, Garcia R et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J. Rheumatol. 26, 432-439 (1999)
92. Kumar S, Benseler SM, Kirby-Allen M, Silverman ED. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics 123, e159-e163 (2009)
93. Reynolds JA, Toescu V, Yee CS, Prabu A, Situnayake D, Gordon C. Effects of rituximab on resistant SLE disease including lung disease. Lupus 1(1), 67-73 (2009)
94. Merill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in patients with moderate to severe active SLE. Results from the randomized, double blind Phase II/III Study EXPLORER (L12)
95. Tucker LB. Review: making the diagnosis of systemic lupus erythemstosus in children and adolescents. Lupus 16, 546 (2007)
96. Kone-Paut I, Piram M, Guillaime S, Tran TA. Review: lupus in adolescence. Lupus 16, 606 (2007)
97. Alvin P. Chronic illness in adolescence: ten relevant questions. Arch. Pediatr. 10, 360-366 (2003)
98. Lilleby V, Lein G, Frey Frosile K et al. Frequency of osteopenia in children and young adults with childhood onset systemic lupus erythematosus. Arthritis Rheum. 52, 2051-2059 (2005)
99. Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E et al. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum. 56(6), 1966-1973 (2007)
100. Brunner HT, Bishnoi A, Barron AC et al. Disease outcomes and ovarian function in childhood-onset systemic lupus erythematosus. Lupus 15, 198-206 (2006)
101. Gonzalez LA, McGwin G Jr, Duran S et al.; LUMINA Study Group. Predictors of premature gonadal failure in patients with systemic lupus erythematosus. Results from LUMINA, a multiethnic US cohort (LUMINA LVIII). Ann. Rheum. Dis. 67(8), 1170-1173 (2008)
102. Dooley MA, Nair R. Therapy insight: preserving fertility in cyclophosphamidetreated patients with rheumatic disease. Nat. Clin. Pract. Rheumatol. 4(5), 250-257 (2008)